Many beliefs have formed around boswellia: from a "natural alternative to ibuprofen" to a "remedy that restores cartilage". Some of them have a partial basis, some are pure marketing. The editorial team has examined the most widespread myths and compared them with what studies actually show.
Myth 1: boswellia completely replaces painkillers
This claim is based on a real fact: boswellic acids inhibit 5-lipoxygenase and thereby reduce the synthesis of inflammatory leukotrienes. However, the mechanism of action does not mean equal efficacy. Classic NSAIDs act on a different pathway - cyclooxygenases - and provide a fast, pronounced analgesic effect.
In clinical studies of osteoarthritis, boswellia moderately reduced pain compared with placebo, but the effect developed over weeks. There are few direct comparisons with NSAIDs, and they do not allow us to claim that boswellia is equivalent in strength of action.
For acute pain after an injury or surgery, boswellia is definitely not a substitute for painkillers. Its potential place is a long-term adjunct for chronic joint pain.
A realistic view: boswellia may help some people reduce their need for painkillers, but this decision should be made together with a doctor, not on one's own.
Myth 2: boswellia restores cartilage
In marketing, formulations such as "regenerates articular cartilage" often appear. The basis for this is laboratory and some clinical data on the reduction of the activity of matrix metalloproteinases that destroy cartilage. In particular, Sengupta and colleagues (2008) reported a reduction of MMP-3 in synovial fluid with 5-Loxin.
However, reducing an enzyme that destroys cartilage is not the same as restoring cartilage. There are currently no studies that would show, on MRI or by other objective methods, an increase in thickness or restoration of cartilage structure in humans.
Even for glucosamine and chondroitin, which have been studied on a much larger scale, large studies such as GAIT (Clegg et al., 2006) did not confirm a pronounced effect on pain in the general group of patients. For structural regeneration the bar of evidence is even higher.
So the correct wording is "may reduce pain and stiffness" rather than "restores cartilage".
Myth 3: the effect comes with the first capsule
Some users expect boswellia to start acting like a painkiller tablet - within an hour. If this does not happen, they consider the product ineffective, or, on the contrary, increase the dose. Both approaches are wrong.
In clinical studies the effect was assessed after 4, 8, 12 weeks, and maximum improvement was most often observed at the end of these periods. For some patented extracts, noticeable changes were reported as early as a few weeks (Vishal et al., 2011), but not within hours.
Hence the conclusion: it makes sense to evaluate boswellia only after 8-12 weeks of regular intake with food. A short course "for a week" will almost certainly not give an informative result.
Myth 4: natural means safe for everyone
Boswellia is indeed generally well tolerated, but it has side effects: gastrointestinal symptoms, allergic reactions, and also isolated reports of liver injury collected in the LiverTox database.
There are also laboratory data on the effect of the resin's components on liver enzymes that metabolize drugs (Frank and Unger, 2006). For people taking anticoagulants, immunosuppressants or other drugs with a narrow therapeutic window, this is a reason for consultation.
Safety during pregnancy and breastfeeding has not been studied. "Traditional use" does not replace controlled studies.
A separate risk is quality. The supplement market is regulated more weakly than the drug market, and products may not match the declared composition.
- Take boswellia with food that contains fats.
- Choose standardized extracts with a known AKBA content.
- Tell your doctor about the supplement if you take medications.
Myths about sport and "stronger" forms
| Claim | What the data say | Verdict |
|---|---|---|
| Boswellia speeds up recovery after training | There are practically no high-quality RCTs on healthy athletes | Not proven |
| Increases strength or endurance | There are no studies with such endpoints | Not proven |
| The more AKBA, the better | Enriched extracts are effective at lower doses, but direct comparison is limited | Partly true |
| Raw resin is "more natural" and therefore better | The composition is unstable, the doses of active substances are unknown | Myth |
| Boswellia is a doping agent | Not on the WADA Prohibited List | Myth |
It is often claimed that boswellia helps "preserve the joints" during heavy training. There are no long-term studies that would confirm this. Extrapolation from osteoarthritis studies in older people to young athletes is incorrect.
The myth about the "strongest extract" also needs clarification. A high concentration of AKBA makes it possible to reduce the dose, but the bioavailability of the acid is low, so the delivery technology and taking it with food are no less important.
As for doping: the substance itself is not banned, but supplement contamination is a real problem, so athletes should choose certified products.
Finally, no supplement compensates for poorly planned loads, lack of sleep or excess weight, which are the main factors of load on the joints.
Editorial conclusions
Boswellia is not a complete replacement for painkillers and does not restore cartilage: only a moderate reduction of pain and stiffness in osteoarthritis has been proven.
The effect develops gradually, over weeks, so a short "trial" is not representative. Natural origin does not guarantee safety for everyone.
For sports recovery and performance there are no high-quality data, and claims about the "strongest" forms should be checked against specific studies.
We recommend reading our articles "The benefits of Boswellia for athletes: the evidence base", "Side effects of Boswellia" and "Boswellia: dosage forms and which to choose".
References
- Sengupta K, Alluri KV, Satish AR, et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. Arthritis Res Ther. 2008;10(4):R85.
- Vishal AA, Mishra A, Raychaudhuri SP. A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of Aflapin in subjects with osteoarthritis of knee. Int J Med Sci. 2011;8(7):615–622.
- Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354(8):795–808.
- Yu G, Xiang W, Zhang T, et al. Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis. BMC Complement Med Ther. 2020;20(1):225.
- LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Boswellia. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases.
- Frank A, Unger M. Analysis of frankincense from various Boswellia species with inhibitory activity on human drug metabolising cytochrome P450 enzymes using liquid chromatography mass spectrometry after automated on-line extraction. J Chromatogr A. 2006;1112(1–2):255–262.
- Ammon HPT. Boswellic acids in chronic inflammatory diseases. Planta Med. 2006;72(12):1100–1116.
Andriy Melnyk
A strength-sports coach and author of programs for beginner and intermediate levels. Writes about training planning.
